Retinal microvascular alterations in patients with active rheumatoid arthritis without cardiovascular risk factors: the potential effects of T cell co-stimulation blockade

被引:1
|
作者
Piantoni, Silvia [1 ]
Regola, Francesca [1 ]
Angeli, Fabrizio [1 ]
Caproli, Alessia [1 ]
Trovati, Annalisa [1 ]
Tomasi, Cesare [1 ]
Chiarini, Giulia [2 ]
Rossini, Claudia [2 ]
Rosei, Claudia Agabiti [2 ]
De Ciuceis, Carolina [2 ]
Franceschini, Franco [1 ]
Muiesan, Maria Lorenza [2 ]
Rizzoni, Damiano [2 ]
Airo, Paolo [1 ]
机构
[1] Univ Brescia, ASST Spedali Civili, Dept Clin & Expt Sci, Rheumatol & Clin immunol Unit, Brescia, Italy
[2] Univ Brescia, Dept Clin & Expt Sci, Internal Med Unit, ASST Spedali Civili, Brescia, Italy
关键词
rheumatoid arthritis; abatacept; microcirculation; cardiovascular risk; inflammation; LUMEN RATIO; EUROPEAN-SOCIETY; BLOOD-PRESSURE; ARTERIOLES; WALL; ATHEROSCLEROSIS; RECOMMENDATIONS; HYPERTENSION; MANAGEMENT; DAMAGE;
D O I
10.3389/fmed.2024.1247024
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background The evaluation of microvascular alterations might provide clinically useful information for patients with an increased cardiovascular (CV) risk, such as those with rheumatoid arthritis (RA), being the small artery remodeling the earliest form of target organ damage in primary CV diseases, such as arterial hypertension. The evaluation of retinal arterioles is a non-invasive technique aimed to identify an early microvascular damage, represented by the increase of the wall-to-lumen ratio (WLR) index. Abatacept (ABA), a T-cell co-stimulator blocker, is used to treat RA. A CV protective action was hypothesized for its peculiar mechanism of action in the modulation of T-cells, potentially involved in the pathogenesis of CV comorbidity. The study aimed to non-invasively investigate morphological characteristics of retinal arterioles in a cohort of RA patients treated with ABA.Materials and methods Seventeen RA patients [median (25th-75thpercentile) age = 58 (48-64) years, baseline 28-joint Disease Activity Score DAS28-C-reactive protein (DAS28-CRP) = 4.4 (3.9-4.6), body mass index (BMI) = 24.2 (23.4-26) kg/m2, rheumatoid factor positive:52.9%, anti-citrullinated peptide autoantibodies positive:76.5%] without known CV risk factors (arterial hypertension, diabetes, hypercholesterolemia, previous CV events, smoking) were evaluated by the adaptive optics imaging system of retinal arterioles before and every 6 months of therapy with ABA (T0, T6 and T12). Office blood pressure evaluation, 24-h ambulatory blood pressure monitoring and tissue-doppler echocardiography were also performed.Results A progressive significant reduction of the WLR of retinal arterioles was observed [T0 = 0.28 (0.25-0.30), T6 = 0.27 (0.24-0.31), T12 = 0.23 (0.23-0.26); p T0 vs. T6 = 0.414; p T6 vs. T12 = 0.02; p T0 vs. T12 = 0.009], without significant variations in other parameters. The T0-T12 reduction of WLR was correlated with that of DAS28-CRP (r:0.789; p = 0.005). Moreover, a significant reduction of diastolic office blood pressure and a trend for reduction of daily pressure measured by ambulatory monitoring were observed.Conclusion In a cohort of RA patients without known CV risk factors, a reduction of retinal microvascular alterations was demonstrated after treatment for 12 months with ABA, in parallel with the reduction of disease activity. These results might suggest the possibility of microvascular abnormalities regression induced by the immune system modulation.
引用
收藏
页数:8
相关论文
共 23 条
  • [1] Abatacept:: a T-cell co-stimulation modulator for the treatment of rheumatoid arthritis
    Oestoer, Andrew J. K.
    CLINICAL RHEUMATOLOGY, 2008, 27 (11) : 1343 - 1353
  • [2] Abatacept: a T-cell co-stimulation modulator for the treatment of rheumatoid arthritis
    Andrew J K Östör
    Clinical Rheumatology, 2008, 27 : 1343 - 1353
  • [3] Safety of T-cell co-stimulation modulation with abatacept in patients with rheumatoid arthritis
    Sibilia, J.
    Westhovens, R.
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2007, 25 (05) : S46 - S56
  • [4] CTLA-4IG AND THE THERAPEUTIC POTENTIAL OF T CELL CO-STIMULATION BLOCKADE
    Graca, Luis
    ACTA REUMATOLOGICA PORTUGUESA, 2008, 33 (03): : 267 - 276
  • [5] Selective modulation of T-cell co-stimulation: a novel mode of action for the treatment of rheumatoid arthritis
    Choy, Ernest H.
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2009, 27 (03) : 510 - 518
  • [6] A novel treatment option in rheumatoid arthritis: abatacept, a selective modulator of T-cell co-stimulation
    Dejaco, Christian
    Duftner, Christina
    Wipfler, Edith
    Schirmer, Michael
    WIENER MEDIZINISCHE WOCHENSCHRIFT, 2009, 159 (3-4) : 70 - 75
  • [7] Subclinical atherosclerosis among rheumatoid arthritis patients without overt cardiovascular risk factors
    Sahari, Narisa Sulaiman
    Shaharir, Syahrul Sazliyana
    Ismail, Mohd Redzuan
    Rajalingham, Sakthiswary
    Said, Mohd Shahrir Mohamed
    MODERN RHEUMATOLOGY, 2014, 24 (06) : 920 - 925
  • [8] Coenzyme Q10 supplementation in patients with rheumatoid arthritis: Are there any effects on cardiovascular risk factors?
    Abdollahzad, Hadi
    Alipour, Beitollah
    Aghdashi, Mir Amir
    Jafarabadi, Mohammad Asghari
    EUROPEAN JOURNAL OF INTEGRATIVE MEDICINE, 2015, 7 (05) : 534 - 539
  • [9] The effects of biologic agents on cardiovascular risk factors and atherosclerosis in rheumatoid arthritis patients: a prospective observational study
    Papamichail, G., V
    Markatseli, T. E.
    Georgiadis, A. N.
    Xydis, V. G.
    Milionis, H.
    Drosos, A. A.
    Voulgari, P. V.
    HEART AND VESSELS, 2022, 37 (12) : 2128 - 2136
  • [10] Sensorineural Hearing Impairment and Subclinical Atherosclerosis in Rheumatoid Arthritis Patients Without Traditional Cardiovascular Risk Factors
    Macias-Reyes, Hector
    Duran-Barragan, Sergio
    Cardenas-Contreras, Cynthia R.
    Chavez-Martin, Cesar G.
    Gomez-Banuelos, Eduardo
    Navarro-Hernandez, Rosa E.
    Yanowsky-Gonzalez, Carlos O.
    Gonzalez-Lopez, Laura
    Gamez-Nava, Jorge I.
    Vazquez-Del Mercado, Monica
    ARCHIVES OF RHEUMATOLOGY, 2016, 31 (03) : 208 - 214